11C-choline PET/CT scan in patients with prostate cancer treated with intermittent ADT: A sequential PET/CT study

Clinical Nuclear Medicine

Volumn 38, Issue 7, 2013, Pages

  Ceci, Francesco ^a   Schiavina, Riccardo ^b   Castellucci, Paolo ^a   Brunocilla, Eugenio ^b   Fuccio, Chiara ^c   Colletti, Patrick M ^d   Ferretti, Alice ^e   Chondrogiannis, Sotirios ^e   Rubello, Domenico ^e   Romagnoli, Daniele ^b   Malizia, Claudio ^a   Martorana, Giuseppe ^b   Fanti, Stefano ^a  

^a Laboratory Medicine   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c IRCCS   (Italy)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

11C Choline PET CT; Androgen deprivation therapy; Prostate cancer; Recurrent prostate cancer

Indexed keywords

BICALUTAMIDE; CHOLINE C 11; GONADORELIN AGONIST; ANTIANDROGEN; CARBON; CHOLINE; DIAGNOSTIC AGENT;

ADULT; AGED; ANTIANDROGEN THERAPY; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG INTERMITTENT THERAPY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LYMPHOMA; MALE; MULTIMODALITY CANCER THERAPY; PET SCANNER; PROSTATE CANCER; PROSTATECTOMY; RECURRENT CANCER; RETROSPECTIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROSTATE TUMOR; RADIOGRAPHY; SCINTISCANNING; VERY ELDERLY; DIAGNOSTIC USE; PROSTATIC NEOPLASMS;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CARBON RADIOISOTOPES; CHOLINE; HUMANS; MALE; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84880372920     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3182952c4c     Document Type: Article

References (26)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59:572-583.
3. Chism DB, Hanlon AL, Horwitz EM, et al. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2004; 59:380-385.
4. Roberts SG, Blute ML, Bergstralh EJ, et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc. 2001;76:576-581.
5. Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169:517-523.
6. Kataja VV, Bergh J. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of prostate cancer. Ann Oncol. 2005; 16(suppl 1):34-36.
7. Fuccio C, Castellucci P, Schiavina R, et al. Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. Eur J Radiol. 2012;81:893-896.
8. Fuccio C, Rubello D, Castellucci P, et al. Choline PET/CT for prostate cancer: Main clinical applications. Eur J Radiol. 2011;80:50-56.
9. Rigatti P, Suardi N, Briganti A, et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol. 2011;60:935-943.
10. Schulman C, Irani J, Aapro M. Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy. M BJU Int. 2012;109(suppl 6):13-21.
11. Calais da Silva FE, Bono AV, Whelan P, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: Results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol. 2009;55:1269-1277.
12. Crook JM, O'Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012;367:895-903.
13. Pascali C, Bogni A, Itawa R, et al. [11C]Methylation on a C18 Sep-Pak cartridge: A convenient way to produce [N-methyl-11C]choline. J Labelled Comp Radiopharm. 2000;49:195-203.
14. Fanti S, Nanni C, Ambrosini V, et al. PET in genitourinary tract cancers. Q J Nucl Med Mol Imaging. 2007;51:260-271.
15. Khan MA, Carter HB, Epstein JI, et al. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol. 2003;170:2274-2278.
16. Sella T, Schwartz LH, Swindle PW, et al. Suspected local recurrence after radical prostatectomy: Endorectal coil MR imaging. Radiology. 2004;233: 379-385.
17. Coakley FV, Teh HS, Qayyum A, et al. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: Preliminary experience. Radiology. 2004;233:441-448.
18. Krause BJ, Souvatzoglou M, Tuncel M, et al. The detection rate of 11Ccholine-PET/TC depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008; 35:18-23.
19. Giovacchini G, Picchio M, Scattoni V, et al. PSA doubling time for prediction of [(11)C] choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37:1106-1116.
20. Castellucci P, Fuccio C, Rubello D, et al. Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase G1.5 ng/ml? Eur J Nucl Med Mol Imaging. 2011;38:55-63.
21. Fuccio C, Castellucci P, Rubello D, et al. Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: The preliminary results of a sequential PET/CT study. Eur J Nucl Med Mol Imaging. 2011;38:1985-1989.
22. Marzola MC, Chondrogiannis S, Ferretti A, et al. Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: Correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution. Clin Nucl Med. 2013;38:26-32.
23. Ceci F, Castellucci P, Mamede M, et al. (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2013;40:149-155.
24. Würschmidt F, Petersen C, Wahl A, et al. [18F]Fluoroethylcholine- PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol. 2011;1:6-44.
25. Tilki D, Reich O, Graser A, et al. 18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol. 2013; 63:792-796.
26. Soyka JD, Muster MA, Schmid DT, et al. Clinical impact of 18F-choline PET/ CT in patients with recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2012;39:936-943.